📰 Solid Tumors News
Page 40 - Solid Tumors News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Solid Tumors. Real-time updates on events, politics, business and more.
November 14, 2022
/PRNewswire/ -- DelveInsights PD-1 and PD-L1 Inhibitors Competitive Landscape – 2022 report provides comprehensive global coverage of available, marketed,...
November 14, 2022
PD-1 and PD-L1 inhibitors clinical trial pipeline constitutes 180+ key companies continuously working towards developing 200+ PD-1 and PD-L1 inhibitors drugs, analyzes DelveInsight LAS
November 10, 2022
Published Comprehensive Preclinical Research on SQZ® AAC Platform in Frontiers in ImmunologyContinued Investigational New Drug-Enabling Activities for SQZ® TAC Platform; Submission Expected in First Half of 2023 with Clinical Batches Intended to be Manufactured on the Company’s Point-of-Care SystemAnticipate Interim...
November 4, 2022
Could oral taxane chemotherapies outperform traditional options? Here, Colin Freund, Modra Pharmaceuticals CEO explores their benefits.
November 2, 2022
Investegate announcements from Faron Pharma. Oy, Faron Announces Poster Presentation at SITC
October 31, 2022
In phase 2 study, relatlimab and nivolumab combination immunotherapy resulted in pathologic complete response rate of 57 percent.
October 11, 2022
Background: Pembrolizumab and olaparib have shown single-agent activity in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC). Objective: To evaluate the efficacy and safety of pembrolizumab plus olaparib in mCRPC. Design, setting, and participants: Cohort A of the phase 1b/2 KEYNOTE-365 study enrolled patients with molecularly unselected, docetaxel-pretreated mCRPC whose disease progressed within 6 mo of screening. Intervention: Pembrolizumab 200 mg intrave...
September 29, 2022
STAMFORD, Conn., Sept. 29, 2022 -- SpringWorks Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases... | September 29, 2022
September 28, 2022
/PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...
September 28, 2022
/PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...